Global Perspectives: Current and Future Management of Breast Cancer
Practice changes and horizon openings from ESMO 2021 and beyond: triple-negative breast cancer, HR+, HER2+ early and metastatic breast cancer.
FACULTY CO-CHAIR
Nadia Harbeck, MD, PhD
Ludwig-Maximilians-University of Munich – Breast Center, Germany
FACULTY CO-CHAIR
Joyce A. O’Shaughnessy, MD
Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, US
Faculty Members
Joseph Gligorov, MD, PhD
Tenon Hospital, Paris, France
Pierfranco Conte, MD
University of Padua, Italy
Guy Jerusalem, MD, PhD
University of Liège, Liège, Belgium
Hope Rugo, MD, FASCO
University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, US
Javier Cortes, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain
William Gradishar, MD
Northwestern Medical Group, Chicago, IL, US
Mark Pegram, MD
Stanford Women’s Cancer Center, Palo Alto, CA, US
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Current and New Treatments in HER2+ Early Breast Cancer (BC)
- Current and New Treatments in HER2+ Metastatic Breast Cancer (mBC)
- Current and Emerging Approaches in HR+, HER2– Early BC
- Current and Emerging Approaches in HR+, HER2– mBC
- Current and Emerging Approaches in Triple-Negative Breast Cancer (TNBC)
- Novel Targets in Breast Cancer